The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials

Journal of Affective Disorders

Volumn 115, Issue 1-2, 2009, Pages 18-26

  Glick, Ira D ^a   Mankoski, Raymond ^b   Eudicone, James M ^b   Marcus, Ronald N ^b   Tran, Quynh Van ^c   Assunção Talbott, Sheila ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Antipsychotic; Atypical; Schizophrenia spectrum

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; CHOLESTEROL; GLUCOSE; HALOPERIDOL; PLACEBO; PROLACTIN; RISPERIDONE;

ABNORMAL INVOLUNTARY MOVEMENTS SCALE; ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; ARTICLE; AUTOMUTILATION; BACKACHE; BARNES AKATHISIA RATING SCALE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE, NEGATIVE, AND GENERAL PSYCHOPATHOLOGY SUBSCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SELF-RATING ANXIETY SCALE; SIDE EFFECT; TREATMENT RESPONSE; TREMOR; VOMITING; WEIGHT CHANGE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 62749205009     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.12.017     Document Type: Article

References (44)

1. APA. Diagnostic and Statistical Manual of Mental Disorders (DSM-IIIR) (1987), American Psychiatric Association, Washington, DC
2. APA. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (2000) Text Revision, Washington, DC
3. APA. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Second Edition (2004)
4. Benabarre A., Vieta E., Colom F., Martinez-Aran A., Reinares M., and C G. Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. Eur. Psychiatry 16 (2001) 167-172
5. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., and Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68 (2007) 843-853
6. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
7. Calabrese J.R., Keck Jr. P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., and Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162 (2005) 1351-1360
8. Crow T. The continuum of psychosis and its implications for the structure of the gene. Br. J. Psychiatry 149 (1986) 419-429
9. Davis J., Chen N., and Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 (2003) 553-564
10. Flynn J., Grieger T., and Benedek D. Pharmacologic treatment of hospitalized patients with schizoaffective disorder. Psychiatr. Serv. 53 (2002) 94-96
11. Glennon R.A., and Dukat M. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York, NY
12. Harrow M., Grossman L.S., Herbener E.S., and Davies E.W. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br. J. Psychiatry 177 (2000) 421-426
13. Hirschfeld R.M., Keck Jr. P.E., Kramer M., Karcher K., Canuso C., Eerdekens M., and Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am. J. Psychiatry 161 (2004) 1057-1065
14. Janicak P., Keck P.J., Davis J., Kasckow J., Tugrul K., Dowd S., Strong J., Sharma R., and Strakowski S. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J. Clin. Psychopharmacology 21 (2001) 360-368
15. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., and Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur. J. Pharmacol. 441 (2002) 137-140
16. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., and Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 483 (2004) 45-53
17. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., and Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63 (2002) 763-771
18. Kane J., Meltzer H., Carson W., McQuade R., Marcus R., and Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J. Clin. Psychiatry 68 (2007) 213-223
19. Kasper S., Lerman M.N., McQuade R.D., Saha A., Carson W.H., Ali M., Archibald D., Ingenito G., Marcus R., and Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6 (2003) 325-337
20. Keck Jr. P.E., McElroy S.L., Strakowski S.M., and West S.A. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology (Berl) 114 (1994) 529-538
21. Keck P.J., Reeves K., Harrigan E., Group, and Z.S. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J. Clin. Psychopharmacology 21 (2001) 27-35
22. Keck Jr. P.E., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A., and Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160 (2003) 1651-1658
23. Keck P.J., Versiani M., Potkin S., West S., Giller E., Ice K., Group, and Z.i.M.S. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry 160 (2003) 741-748
24. Keck P.E., Calabrese J.R., McQuade R.D., Carson W.H., Carlson B.X., Rollin L.M., Marcus R.N., and Sanchez R. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 67 (2006) 626-637
25. Keck P., Calabrese J., McIntyre R., McQuade R., Carson W., Eudicone J., Carlson B., Marcus R., and Sanchez R. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J. Clin. Psychiatry. 68 (2007) 1480-1491
26. Kern R.S., Green M.F., Cornblatt B.A., Owen J.R., McQuade R.D., Carson W.H., Ali M., and Marcus R. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 187 (2006) 312-320
27. Lasser R., Bossie C., Gharabawi G., Eerdekens M., and Nasrallah H. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J. Affect. Disord. 83 (2004) 263-275
28. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., and Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 112 (1993) S40-54
29. Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., Trivedi M.H., Thase M.E., and Berman R.M. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol 28 (2008) 156-165
30. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., and Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61 (2003) 123-136
31. Marneros A. Schizoaffective disorder: clinical aspects, differential diagnosis, and treatment. Curr. Psychiatry Rep. 5 (2003) 202-205
32. McElroy S., Keck P.J., and Strakowski S. An overview of the treatment of schizoaffective disorder. J. Clin. Psychiatry 60 (1999) 16-21
33. McEvoy J., Daniel D., Carson W.J., McQuade R., and Marcus R. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J. Psychiatr. Res. 41 (2007) 895-905
34. Millan M.J. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J. Pharmacol. Exp. Ther. 295 (2000) 853-861
35. Pigott T.A., Carson W.H., Saha A.R., Torbeyns A.F., Stock E.G., and Ingenito G.G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 64 (2003) 1048-1056
36. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., and Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60 (2003) 681-690
37. Rao M.L., and Moller H.J. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. Neuropsychobiology 30 (1994) 160-172
38. Sachs G., Sanchez R., Marcus R., Stock E., McQuade R., Carson W., Abou-Gharbia N., Impellizzeri C., Kaplita S., Rollin L., and Iwamoto T. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J. Psychopharmacol. 20 (2006) 536-546
39. Tohen M., Zhang F., Keck P., Feldman P., Risser R., Tran P., and Breier A. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J. Affect. Disord. 67 (2001) 133-140
40. Tohen M., Vieta E., Calabrese J., Ketter T., Sachs G., Bowden C., Mitchell P., Centorrino F., Risser R., Baker R., Evans A., Beymer K., Dube S., Tollefson G., and Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60 1072 (2003) 1079-1088 Erratum in:
41. Arch. Gen. Psychiatry 1061 (2004) 1176 Feb
42. Tran P.V., Tollefson G.D., Sanger T.M., Lu Y., Berg P.H., and Beasley Jr. C.M. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. Br. J. Psychiatry 174 (1999) 15-22
43. Vieta E., Goikolea J.M., Corbella B., Benabarre A., Reinares M., Martinez G., Fernandez A., Colom F., Martinez-Aran A., and Torrent C. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J. Clin. Psychiatry 62 (2001) 818-825
44. Vieta E., Bourin M., Sanchez R., Marcus R., Stock E., McQuade R.D., Carson W., Abou-Gharbia N., Swanink R., Iwamoto T., and on behalf of the Aripiprazole Study Group. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br. J. Psychiatry 187 (2005) 235-242